Pharmaceutical stocks underperform broad market by 10% in 2026 H2

Heightened political risk from Medicare for All rhetoric and rising progressive influence in Congress will pressure pharmaceutical stock valuations through the second half of 2026. Stocks like Pfizer, Merck, and Eli Lilly will see relative underperformance as investors price in regulatory risk.

price · Prediction Market

Implied probability (Yes)

70%

Closes

2026-12-31

More price markets

• Samsung Electronics market cap to exceed $1.2T by Q3 2026 — 78% Yes
• Cisco stock to rise above $65 by Q3 2026 — 72% Yes
• Private jet charter prices increase 20% in 2027 — 75% Yes
• X’s stock price rises 10% within 3 months of History tab launch — 55% Yes
• TSK enters top 5 Spanish engineering firms by market cap — 60% Yes
• Gas tax suspension fails to lower pump prices by 2027 — 75% Yes
• Gasoline prices fall below $4.00 per gallon by October 2026 — 70% Yes
• Ford stock volatility exceeds 60% annualized within 6 months — 75% Yes

Browse all price markets →